July 17, 2019 10:22 AM EDTUpdated 02:28 PM
News Briefing

Seer en­tices ex FDA com­mis­sion­er Mc­Clel­lan to its board; Van­da tests tradip­i­tant in mo­tion sick­ness study

Natalie Grover

Reporter

→ The re­volv­ing door be­tween gov­ern­ment and the bio­phar­ma­ceu­ti­cal in­dus­try is spin­ning. On Wednes­day, life sci­ences and health da­ta com­pa­ny Seer un­veiled that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times